"David Oubre, MD and the medical team at Pontchartrain Cancer Center are specialists in the treatment and prevention of cancer and blood disorders. Medical Oncology is the field of medicine which specializes in the diagnosis and treatment of cancer. Cancer is treated in numerous ways: chemotherapy; immunotherapy; surgery; radiation therapy; along with new therapies that are continuously evolving. Our physicians are experts in prescribing and the supervision of chemotherapy and immunotherapy administration. Chemotherapy or biological therapy is defined as any medication which is given either by mouth, injection or intravenously to kill or stop the formation of cancer cells."

During the past decade, Pontchartrain Cancer Center conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 3 clinical trials were completed, i.e. on average, 16.7% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 3 clinical trials were completed. i.e. 30% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Pontchartrain Cancer Center" #1 sponsor was "Janssen Research & Development, LLC" with 3 trials, followed by "Spectrum Pharmaceuticals, Inc" with 2 trials sponsored, "Tempus Labs" with 2 trials sponsored, "American Society of Clinical Oncology" with 1 trials sponsored and "Calithera Biosciences, Inc" with 1 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Pontchartrain Cancer Center" #1 collaborator was "BeiGene" with 1 trials as a collaborator, "GlaxoSmithKline" with 1 trials as a collaborator and "Janssen, LP" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Pontchartrain Cancer Center" are "Breast Cancer" (4 trials), "Neutropenia" (2 trials), "Pancreatic Cancer" (2 trials), "Advanced Breast Cancer" (1 trials) and "Androgen-Independent Prostatic Cancer" (1 trials). Many other conditions were trialed in "Pontchartrain Cancer Center" in a lesser frequency.

Most popular intervention types in "Pontchartrain Cancer Center" are "Drug" (12 trials), "Other" (3 trials), "Biological" (2 trials), "Device" (1 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Docetaxel" (4 trials), "Cyclophosphamide" (2 trials), "Pegfilgrastim" (2 trials), "Pemetrexed" (2 trials) and "Placebo" (2 trials). Other intervention names were less common.

The vast majority of trials in "Pontchartrain Cancer Center" are 16 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Pontchartrain Cancer Center". undefined are not yet recruiting, 8 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Pontchartrain Cancer Center, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Pontchartrain Cancer Center, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".